

Title:

Could ViRexx Medical's 'Linked Recognition' Research Lead to a Cancer Vaccine?

Word Count:

1078

Summary:

Dr. Lorne Tyrrell pioneered lamivudine as the standard treatment for hepatitis B virus (HBV).

Keywords:

Cancer, hepatitis, hepatitis b, infections, disease, immune system, HBV, HIV, virus, medical,

Article Body:

A SCIENTIST'S 20-YEAR UNFINISHED JOURNEY TO TREAT HBV MAY OPEN THE DOOR TO A NEW CLASS OF FLEX

While preparing a lecture in biochemistry and virology for his graduate students at the Univer

After studying their duck model theory, Tyrrell speculated if the hepatitis B virus (HBV) might

More than 350 million people across the world, especially in Asia, now had new hope, some for

Licensed in 1998, lamivudine is now used in 120 countries as a standard therapy for chronic HB

HIS UNANSWERED QUESTIONS LAUNCHED A NEW HBV INVESTIGATION

Despite the awards and recognition, questions remained for Dr. Tyrrell about the shortcomings

Having screened lamivudine for use in Hepatitis B at Glaxo's research lab at the University of

^How do you break tolerance?~ Tyrrell asked himself, hoping to develop a way to stimulate an i

^That's where we came in with the Chimigen technology,~ Tyrrell said. ^The dendritic cells ha

LINK RECOGNITION MAY HOLD THE KEY

Dr. Rajan George, ViRexx Medical's vice president of research and development, told us, ^The d

Research at Tokyo's Cancer Institute Hospital, published in 1987 in Nippon Sanka Fujinka Gakka

Dr. Tyrrell's work at ViRexx Medical with Dr. George suggested the linked-recognition theory m

END OF PART ONE

This is a demo version of txt2pdf v.10.1

Developed by SANFACE Software <http://www.sanface.com/>

Available at <http://www.sanface.com/txt2pdf.html>